ReviewFrontiers in immunology2022
Interleukin-17 as a potential therapeutic target for chronic pain.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Mapping the immune and epigenetic landscape of medication-overuse headache (MOH): a systematic review.Frontiers in immunology · 2026Pooled it
- Neuropathic Pain Management Using Novel Biologics in Moderate-to-Severe Hidradenitis Suppurativa.Current pain and headache reports · 2026Review
- Integrated single-cell and spatial transcriptomics reveal stromal-immune-vascular crosstalk in patients with interstitial cystitis/bladder pain syndrome.Experimental & molecular medicine · 2026Article
- A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer's Disease?Dermatology and therapy · 2026Review
- Depletion of p75NTR in Schwann Cells Driven by Inflammation Mediates Cutaneous Pain in Psoriasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Differences in Itch Quality Between Interleukin-31 and Thymus and Activation-Regulated Chemokine of Japanese Atopic Dermatitis.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Inflammation and pain as interconnected targets in axial spondyloarthritis.Nature reviews. Rheumatology · 2026Review
- Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study.Scientific reports · 2026Observational
- Sex-specific lateralization of the effects of exogenously-induced neuroimmune activation in the amygdala on pain-like behaviors.Frontiers in pharmacology · 2026Article
- The pivotal role of immunometabolism in diabetic neuropathy and its potential therapeutic strategies.Frontiers in endocrinology · 2026Review
- Cellular and molecular changes in the skin driving increased nociception and pain during burn injury and repair.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Immunopathological mechanisms and targeted intervention strategies for chronic chikungunya arthritis: from viral persistence to autoimmunity.Frontiers in immunology · 2026Review
- Analysis of the circRNA/lncRNA-miRNA-mRNA Networks of Action of Fire Needle Acupuncture in Relieving Chemotherapy-Induced Neuropathic Pain.Journal of pain research · 2026Article
- Exploratory evaluation of miR-146, inflammatory biomarkers, and subjective cognitive symptoms in chronic migraine.Turkish journal of medical sciences · 2026Article
- Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.Pain and therapy · 2025Article
- The Association of IL-17RC Polymorphisms rs708567 and rs76999397 With Acute Lymphoblastic Leukaemia.International journal of immunogenetics · 2025Article
- Pain and Sleep Biomarkers in Participants Undergoing Orthopedic Surgeries.International journal of molecular sciences · 2025Observational
- Sex Differences in the Regulation of Interleukins in Chronic Pain: A Widely Recognized but Difficult-to-Tackle Factor.International journal of molecular sciences · 2025Review
- Focal Adhesion Kinase Inhibition Ameliorates Burn Injury-Induced Chronic Pain in Rats.Molecular neurobiology · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain remains to be a clinical challenge and is recognized as a major health problem with varying impacts on quality of life. Currently, the first-line therapy for chronic pain is opioids, which are often accompanied by unwanted psychoactive side effects. Thus, new and effective treatments for chronic pain are urgently needed and eagerly pursued. Inflammatory cytokines, especially interleukin-17 (IL-17), are reportedly potential therapeutic targets owing to their pivotal role in chronic pain from the neuroinflammation perspective. Recently, substantial evidence confirmed that IL-17 and IL-17 receptors (IL-17Rs) were increased in neuropathic, inflammatory, and cancer pain models. Notably, IL-17/IL-17R antibodies also reportedly relieve or cure inflammatory- and pain-related diseases. However, existing studies have reported controversial results regarding IL-17/IL-17Rs as potential therapeutic targets in diverse animal models of chronic pain. In this review, we present a summary of published studies and discuss the evidence, from basic to clinical to research, regarding the role and mechanism of action between IL-17 and diverse kinds of chronic pain in animal models and clinical patients. Furthermore, we evaluated IL-17-based therapy as a potential therapeutic strategy for inflammatory- and pain-related disease. Importantly, we also discussed clinical trials of IL-17/IL-17R targeting monoclonal antibodies. Overall, we found that IL-17 is a potential therapeutic target for chronic pain from the perspective of neuroinflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.